XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO(TM) (clindamycin phosphate) Vaginal Gel 2%

Stock Information for Southern Calif Bancorp

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Southern Calif Bancorp

XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
Actym Therapeutics Appoints Thomas Smart as CEO
XOMA Corporation Announces Closing of Tender Offer
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE - AGTI), Landos Biopharma, Inc. (Nasdaq - LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Kinnate Biopharma Inc. (Nasdaq - KNTE)
XOMA Declares Quarterly Preferred Stock Dividends
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.